Desmopressin

Desmopressin (DDAVP) — Synthetic V2-Selective Vasopressin Analog

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

A synthetic vasopressin analogue used in several FDA-approved formulations for conditions including central diabetes insipidus, selected bleeding disorders, primary nocturnal enuresis, and nocturia due to nocturnal polyuria. Approved uses and safety differ by formulation.

Plain English

Desmopressin is a modified version of vasopressin designed to strongly reduce urine production without producing the same degree of blood-vessel constriction as natural vasopressin. Different desmopressin products are used for different purposes, including diabetes insipidus, certain bleeding disorders, bedwetting, and some forms of nighttime urination. The exact indication and safety profile depend on the formulation.

Overview

Desmopressin is a synthetic analogue of arginine vasopressin engineered to provide strong antidiuretic activity with substantially reduced vasopressor activity. It acts primarily through V2 receptors in the kidney to increase water reabsorption. Desmopressin can also increase circulating factor VIII and von Willebrand factor, which supports its use in selected bleeding disorders. FDA-approved indications differ by formulation, so injectable, oral, nasal, and sublingual desmopressin products should not be treated as interchangeable.

Research Summary

Desmopressin has extensive human clinical use across several established indications. Injectable formulations are used for central diabetes insipidus and selected patients with hemophilia A or type 1 von Willebrand disease. Oral tablets are used for central diabetes insipidus and primary nocturnal enuresis, while NOCDURNA is specifically approved for nocturia due to nocturnal polyuria in adults. Hyponatremia and water intoxication are the major safety concerns across formulations and can become severe or life-threatening. Formulation-specific labeling is important because indications, dosing, pharmacokinetics, and risk differ substantially between injectable, oral, nasal, and sublingual products.

Research Areas

  • Central diabetes insipidus
  • Nocturnal enuresis
  • von Willebrand disease
  • Hemophilia A
  • Vasopressin-related CNS research
  • Nocturia

Safety & Risks

Serious Risks

  • Desmopressin can cause severe, potentially life-threatening hyponatremia, including seizures, coma, respiratory arrest, or death
  • Fluid intake restriction and serum sodium monitoring are important with formulations carrying significant hyponatremia risk
  • Moderate to severe renal impairment, current or prior hyponatremia, SIADH, polydipsia, and certain interacting drugs or illnesses can substantially increase hyponatremia risk
  • Injectable desmopressin can cause hypotension or hypertension and requires appropriate monitoring in susceptible patients
  • Desmopressin can increase thrombosis risk in patients with type IIB von Willebrand disease and is not indicated for that condition
  • Severe hypersensitivity reactions can occur

Reported Side Effects

  • Headache
  • Nausea
  • Abdominal discomfort
  • Facial flushing
  • Nasal irritation or congestion with intranasal formulations
  • Fluid retention
  • Hyponatremia
United States
FDA-approved desmopressin products have formulation-specific indications. Injectable desmopressin is approved for central diabetes insipidus and selected patients with hemophilia A or type 1 von Willebrand disease. Oral tablets are approved for central diabetes insipidus and primary nocturnal enuresis. NOCDURNA is approved for nocturia due to nocturnal polyuria in adults. Desmopressin nasal spray is not an indicated formulation for primary nocturnal enuresis because of increased hyponatremia risk.
United Kingdom
MHRA-approved; prescription only; Nocdurna approved for nocturia due to nocturnal polyuria
Australia
TGA-approved prescription drug for DI, enuresis, and bleeding disorders
Canada
Health Canada-approved; prescription only

Citations & Sources